Shield Therapeutics plc (LSE: STX), a commercial-stage pharmaceutical company specialising in iron deficiency treatment, has published its unaudited trading update for the three months ended 30 September 2026. Group net revenue reached $11.5M, with US ACCRUFeR® net revenue rising 5% quarter-on-quarter to $10.8M. Crucially, the company also confirmed it has taken full commercial responsibility for ACCRUFeR® across the United States from 1 October 2026, a structural change the board describes as entering a new phase of value creation. Investors should note the company has revised its FY 2026 guidance, no longer expecting to achieve operating profitability for the full year.

Key Points

  • Shield Therapeutics plc (LSE: STX) — commercial-stage specialty pharmaceutical company focused on iron deficiency
  • US ACCRUFeR® (ferric maltol) net revenue rose 5% quarter-on-quarter to $10.8M in Q3 2026; average net revenue per prescription increased 4% to $217
  • Full US commercial control assumed from 1 October 2026, expanding the sales force to 80 territories; FY 2026 guidance revised to a single-digit US dollar million loss
  • Investors will be watching Q4 and FY 2026 results for 2027 profitability guidance and evidence that the expanded US sales force is driving prescription growth

ACCRUFeR® US Net Revenue Grows 5% as Average Net Revenue Per Prescription Reaches $217

Shield's core US business continued its upward trajectory in Q3 2026, with ACCRUFeR® net revenue rising 5% to $10.8M from $10.3M in Q2 2026. Average net revenue per prescription improved 4% to $217 (Q2 2026: $208), reflecting the company's deliberate shift towards commercially insured patients. Dispensed prescriptions held steady at approximately 49,000, matching the prior quarter, despite an ongoing reduction in Medicaid volumes following prior authorisation requirements introduced in New York's Medicaid programme in April 2026. Ex-US revenue was $0.7M, down from $1.0M in Q2 2026. Cash stood at $6.8M at quarter end.

Commercial Prescription Mix Improves to 80% as Medicaid Transition Strategy Delivers Results

The prescription mix reached approximately 80% commercial and 20% Medicaid for the profitable retail, non-consignment business in Q3 2026. Between Q1 and Q3 2026, commercial prescriptions increased by 17%, offsetting a 56% decline in Medicaid prescriptions over the same period. For the nine months to 30 September 2026, commercial prescriptions grew 19% year-on-year while total prescriptions rose 3%. The announcement states that Q3 2026 marks the final quarter impacted by the New York Medicaid prior authorisation mandate changes, suggesting the headwind from that regulatory shift should not persist into Q4. A paediatric safety and efficacy manuscript was published in Pediatric Drugs on 15 July 2026.

Shield Assumes Full US Control of ACCRUFeR® from 1 October 2026, Expanding to 80 Sales Territories

From 1 October 2026, Shield assumed full commercial responsibility for ACCRUFeR® in the United States, incorporating the entire sales force across 80 territories. The announcement states this transaction materially improves gross margins, increases revenue retention through a lower royalty rate, and enhances the company's path toward sustainable profitability. With ACCRUFeR® described as the number-one branded prescription oral iron in the US market — drawing on IQVIA Xponent PlanTrak data — and patent coverage extending until the mid-2030s, the structural economics of the business have shifted. Michael Jensen joined as Chief Financial Officer on 1 September 2026.

FY 2026 Profitability Guidance Revised to Single-Digit US Dollar Million Loss

Shield has revised its full-year 2026 guidance, stating it no longer expects to achieve operating profitability for the year ending 31 December 2026, as previously guided. The company now anticipates reporting a single-digit US dollar million loss for FY 2026, primarily reflecting additional commercial costs associated with assuming full US control of ACCRUFeR® from 1 October 2026, including the expanded sales force. The board stated that achieving sustainable profitability as soon as possible remains its key priority. Guidance for 2027 will be provided alongside the Q4 and FY 2026 trading update. Investors may be watching closely for that guidance to assess the timeline to breakeven.